Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "AN - Anorexia nervosa" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low weight, fear of gaining weight, and a strong desire to be thin, resulting in food restriction.
Cytokine antagonists for neurological and neuropsychiatric disorders
Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, postpartum depression, and schizoaffective illness.
Owner:TACT IP
Method for treating cachexia with retinoid ligands
InactiveUS20070185055A1BiocideSilicon compound active ingredientsRetinoidObstructive Pulmonary Diseases
The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
Owner:JIANG GUANG LIANG +2
Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.
Owner:ALBANY MOLECULAR RESEARCH INC
Treatment of anorexia nervosa and bulimia
InactiveUS20020187932A1Significantly enrichedReduce signalingNervous disorderPeptide/protein ingredientsPharmacologyAN - Anorexia nervosa
According to the present invention, a method for the treatment of anoxeria nervosa (AN) or bulimia comprises administering to a patient having AN or bulimia an effective amount of an inverse agonist on MC4-r.
Owner:ELAN DRUG DELIVERY LTD
Androgen activity antagonists as therapies for anorexia, anorexia nervosa and disorders characterized by a pathologically underweight condition
InactiveUS20010020002A1Excessive activityReduce secretionBiocidePeptide/protein ingredientsDiseaseAndrogen
The present invention relates to the treatment of conditions characterized by loss of appetite (anorexia) and / or pathological weight loss by administering a therapeutically effective amount of an agent that modulates androgen activity. The present invention further relates to the treatment and prevention of anorexia nervosa with such agents.
Owner:VELA PHARMA
Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
InactiveUS20070015828A1Eliminate side effectsBiocideNervous disorderNorepinephrine reuptake inhibitorVisceral pain
Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH
Method of treatment using novel antagonists or inverse agonists at opioid receptors
A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.
Owner:IGNAR DIANE MICHELE
Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them
ActiveUS20080132486A1Easily determining tailoringSimple designBiocideNervous disorderDiseaseAlcoholisms
One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Cytokine antagonists for neurological and neuropsychiatric disorders
InactiveUS20060051381A1Peptide/protein ingredientsAntibody mimetics/scaffoldsWhite blood cellREFLEX DECREASE
Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, post-partum depression, and schizoaffective illness.
Owner:TACT IP
Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Application of bifidobacterium lactis in prevention and treatment of mental disorder
PendingCN112956696AImprove permeabilityLower LPSMilk preparationNervous disorderBiotechnologyDisease
The invention relates to application of bifidobacterium lactis in prevention and treatment of mental disorder, the bifidobacterium lactis is bifidobacterium lactis BL-11, and the preservation number of the bifidobacterium lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bifidobacterium lactis provided by the invention can be used for improving the intestinal permeability and reducing the levels of LPS and D-lactic acid in blood, so that the effect of preventing and treating mental disorders is achieved, and the mental disorders comprise anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette disease and Escherberg syndrome.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD
Serotonin and norepinephrine reuptake inhibitor and uses thereof
InactiveUS20070015824A1Low level of undesirable side-effectsBiocideOrganic chemistryNorepinephrine reuptake inhibitorDepressant
Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH
Imidazopyrimidinyl and imidazopyri dinyl derivatives
InactiveUS7045529B2Convenient treatmentBiocideNervous disorderHuntingtons choreaImmunodeficiency virus
Provided herein are compounds of the formula (I): as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.
Owner:BRISTOL MYERS SQUIBB PHARMA CO
Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Composition and formulations and their use as nociceptic, anti-axniolytic and anabolic agents
Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammatories, anti-migraine agents, anti-emetics, diuretics, high protein composites, and the like. The products are suitable as nociceptics and for the treatment of wasting disorders, bulimia, anorexia nervosa, anxiety, irritability and other symptoms associated with Pre Menstrual Syndrome, as well as for administration either in conjunction with steroids or to compensate adenosine depletion and / or bizarre behavior or aggression common in steroid users.
Owner:EAST CAROLINA UNIVERISTY
Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
Owner:WYETH LLC
Beta-carboline selective monoamine oxidase B inhibitor and pharmaceutical application thereof
The invention discloses beta-carboline derivatives with structural characteristics shown in a formula (I), and also discloses pharmaceutically acceptable salts of the beta-carboline derivatives, a preparation method of the beta-carboline derivatives and application of the beta-carboline derivatives as selective monoamine oxidase B inhibitors. The compounds of the invention are useful for the treatment of neuropsychiatric and degenerative diseases modulated by selective monoamine oxidase B inhibitors, including Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder, depression, schizophrenia, anorexia nervosa and migraine.
Owner:陈冬寅
CB1 antagonists and inverse agonists
InactiveUS20080027087A1Minimizing metabolic risk factorEfficient dosingBiocideOrganic chemistryMetabolic syndromeAN - Anorexia nervosa
The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.
Owner:AMPLA PHARMA
Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan
Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH
Method of screening preventives or remedies for obesity
InactiveUS7247440B2Reduced expression levelCompound screeningCell receptors/surface-antigens/surface-determinantsBound propertyObesity
The present invention provides preventive / therapeutic agents for anorexia nervosa and preventive / therapeutic agents for obesity. More specifically, the present invention provides a method and kit for screening a compound or its salt that changes the binding properties of GPR7 to a polypeptide capable of binding specifically to GPR7.
Owner:TAKEDA PHARMA CO LTD
Traditional Chinese medicine mixture for treating anorexia nervosa
InactiveCN104524277ANo significant differenceComparableDigestive systemPlant ingredientsPolygonum posumbuElaeagnus
The invention discloses a traditional Chinese medicine mixture for treating anorexia nervosa. The mixture is prepared from the following medicinal materials in parts by weight: 6-9 parts of oroxylum indicum, 1-3 parts of neroli, 5-8 parts of semen aesculi, 6-9 parts of tribulus terrestris, 1-3 parts of peganum harmala, 6-9 parts of peliosanthestetaandr, 15-20 parts of mariscus umbellatus, 12-15 parts of conespike flemingia roots, 10-12 parts of green fig roots, 15-20 parts of polygonum posumbu, 1-3 parts of herpetospermum seeds, 9-12 parts of elaeagnus pungens, 12-15 parts of blueflower cicerbita roots, 12-15 parts of Siberian nitraria fruits, 9-12 parts of dwarf cowlily seeds, 9-12parts of caesalpinia, 15-20 parts of phaenosperma globosa, 9-12 parts of bilobate grewia, 12-15 parts of roots of white flowered bittercress and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention for treating liver-stagnation with spleen-deficiency type anorexia nervosa is high in effective rate and reliable in curative effect and anorexia nervosa does not relapse after being healed.
Owner:JINING UNIV
Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
ActiveUS10918632B2Organic active ingredientsMetabolism disorderMetabotropic glutamate receptorAnorectic
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Medicinal composition for treating anorexia nervosa
The invention discloses a medicinal composition for treating anorexia nervosa, which consists of extracts of red infested rice, Chinese thorowax root and epimedium herb. The extracts are prepared by the prior method, comprise but are not limited to aqueous extract, alcohol extract, macroporous resin column extract by water extraction and alcohol sedimentation or a supercritical extraction method. The medicinal composition is added with the prior accessories and made into clinically acceptable medicament formulations according to the prior process. The medicinal composition has remarkable effect of treating the anorexia nervosa and no side effects.
Owner:BEIJING WBL PEKING UNIV BIOTECH
Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
InactiveUS20090042874A1Shorten the incubation periodIncreased serotonin levelBiocideNervous disorderDiseaseAttention deficits
The invention provides compounds of the Formula:that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
CB1 antagonists and inverse agonists
InactiveUS20090036426A1Minimizing metabolic risk factorMinimize risk factorBiocideMetabolism disorderMetabolic syndromeAN - Anorexia nervosa
The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention conjointly with zonisamide, naltrexone, or a pharmaceutically acceptable salt thereof. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention conjointly with zonisamide, naltrexone, or a pharmaceutically acceptable salt thereof.
Owner:AMPLA PHARMA
Antidepressant piperidine derivatives of heterocyclefused benzodioxans
Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
2-halo-5-alkynyl-pyridyl nicotinic ligands
Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.
Owner:GEORGETOWN UNIV
2-Halo-5-ynyl-pyridylnicotinyl ligands
Heterocyclic compounds that are ligands for nicotinic acetylcholine receptors are disclosed. The compounds are useful in the treatment of mammals suffering from any of a variety of therapeutic indications including Alzheimer's disease, Parkinson's disease, movement disorders, Tourette's syndrome , Schizophrenia, Attention Deficit Disorder, Anxiety, Pain, Depression, Compulsive Disorder, Substance Abuse, Alcoholism, Amnesia, Pseudodementia, Gunther Syndrome, Migraine, Bulimia, Obesity, Menstrual Pre or LPS, Tobacco Abuse, Post Traumatic Syndrome, Social Phobia, Chronic Fatigue Syndrome, Premature Ejaculation, Erectile Dysfunction, Anorexia Nervosa, Sleep Disorders, Autism, Mutism, Trichotillomania, and Hypothyroidism body temperature.
Owner:GEORGETOWN UNIV
Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
Compounds of the formula useful for the treatment of diseases such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com